{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:53:42Z","timestamp":1791402822625,"version":"4.3.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"DOI":"10.1007\/s00393-026-01878-2","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:07:11Z","timestamp":1791400031000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Myositis unter Immuncheckpoint-Inhibitor-Therapie","Myositis induced by immune checkpoint inhibitor therapy"],"prefix":"10.1007","author":[{"given":"Karolina","family":"Gente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kastriot","family":"Kastrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga","family":"Lechner-Radner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Hasseli-Fr\u00e4bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"1878_CR1","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/art.41604","volume":"73","author":"J Aldrich","year":"2021","unstructured":"Aldrich\u00a0J, Pundole\u00a0X, Tummala\u00a0S et\u00a0al (2021) Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors. Arthritis Rheumatol 73:866\u2013874","journal-title":"Arthritis Rheumatol"},{"key":"1878_CR2","doi-asserted-by":"crossref","unstructured":"Benesova K, Leipe J (2020) Diagnostik und Management rheumatischer irAEs: Rheumatologische Nebenwirkungen der Checkpoint-Inhibition erkennen und behandeln. Z Rheumatol im Druck","DOI":"10.1007\/s00393-020-00825-z"},{"key":"1878_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000529","volume":"4","author":"K Benesova","year":"2019","unstructured":"Benesova\u00a0K, Lorenz\u00a0HM, Leipe\u00a0J et\u00a0al (2019) How I treat cancer: treatment of rheumatological side effects of immunotherapy. ESMO Open 4:e000529","journal-title":"ESMO Open"},{"key":"1878_CR4","unstructured":"Deutsche Gesellschaft F\u00fcr H\u00e4matologie Und Medizinische Onkologie (Dgho) (2025) S3-Leitlinie Supportive Therapie bei onkologischen PatientInnen. AWMF. In: https:\/\/register.awmf.org\/assets\/guidelines\/032-054OLl_S3_Supportive-Therapie-bei-onkologischen-PatientInnen_2026-06.pdf"},{"key":"1878_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100317","volume":"6","author":"B Jordan","year":"2021","unstructured":"Jordan\u00a0B, Benesova\u00a0K, Hassel\u00a0JC et\u00a0al (2021) How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors. ESMO Open 6:100317","journal-title":"ESMO Open"},{"key":"1878_CR6","doi-asserted-by":"crossref","unstructured":"Kostine M, Finckh A, Bingham CO, 3rd et al. (2021) EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis 80:36-48.","DOI":"10.1136\/annrheumdis-2020-217139"},{"key":"1878_CR7","doi-asserted-by":"crossref","unstructured":"Leipe J, Mariette X (2019) Management of rheumatic complications of ICI therapy - a rheumatology viewpoint. Rheumatolology (Oxford) 58:vii49-vii58","DOI":"10.1093\/rheumatology\/kez360"},{"key":"1878_CR8","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider\u00a0BJ, Naidoo\u00a0J, Santomasso\u00a0BD et\u00a0al (2021) Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J\u00a0Clin Oncol 39:4073\u20134126","journal-title":"J Clin Oncol"},{"key":"1878_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaa181","volume":"2","author":"S Shelly","year":"2020","unstructured":"Shelly\u00a0S, Triplett\u00a0JD, Pinto\u00a0MV et\u00a0al (2020) Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy. Brain Commun 2:fcaa181","journal-title":"Brain Commun"},{"key":"1878_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00262-017-2069-9","volume":"67","author":"K Buder-Bakhaya","year":"2018","unstructured":"Buder-Bakhaya\u00a0K, Benesova\u00a0K, Schulz\u00a0C et\u00a0al (2018) Characterization of arthralgia induced by PD\u20111 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol Immunother 67:175\u2013182","journal-title":"Cancer Immunol Immunother"},{"key":"1878_CR11","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/acr.23177","volume":"69","author":"LC Cappelli","year":"2017","unstructured":"Cappelli\u00a0LC, Gutierrez\u00a0AK, Bingham\u00a0CO 3rd et\u00a0al (2017) Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. Arthritis Care Res (Hoboken) 69:1751\u20131763","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1878_CR12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","volume":"77","author":"M Kostine","year":"2018","unstructured":"Kostine\u00a0M, Rouxel\u00a0L, Barnetche\u00a0T et\u00a0al (2018) Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a\u00a0single-centre prospective cohort study. Ann Rheum Dis 77:393\u2013398","journal-title":"Ann Rheum Dis"},{"key":"1878_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102536","volume":"70","author":"P Gougis","year":"2024","unstructured":"Gougis\u00a0P, Jochum\u00a0F, Abbar\u00a0B et\u00a0al (2024) Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade\u2011a worldwide perspective. EClinicalMedicine 70:102536","journal-title":"EClinicalMedicine"},{"key":"1878_CR14","unstructured":"National Comprehensive Cancer Network Nccn (2026) Management of Immune Checkpoint Inhibitor-Related Toxicities. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1548. Zugegriffen: 19. M\u00e4rz 2026"},{"key":"1878_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltab014","volume":"1","author":"ZD Drobni","year":"2021","unstructured":"Drobni\u00a0ZD, Murphy\u00a0SP, Alvi\u00a0RM et\u00a0al (2021) Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. Immunother Adv 1:ltab014","journal-title":"Immunother Adv"},{"key":"1878_CR16","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/eurheartj\/ehaf682","volume":"47","author":"JE Salem","year":"2026","unstructured":"Salem\u00a0JE, Ajrouche\u00a0A, Rozes\u00a0A et\u00a0al (2026) Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a\u00a0French nationwide study. Eur Heart J 47:1014\u20131030","journal-title":"Eur Heart J"},{"key":"1878_CR17","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","volume":"611","author":"ML Axelrod","year":"2022","unstructured":"Axelrod\u00a0ML, Meijers\u00a0WC, Screever\u00a0EM et\u00a0al (2022) T cells specific for alpha-myosin drive immunotherapy-related myocarditis. Nature 611:818\u2013826","journal-title":"Nature"},{"key":"1878_CR18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210031","volume":"103","author":"G Beecher","year":"2024","unstructured":"Beecher\u00a0G, Pinal-Fernandez\u00a0I, Mammen\u00a0AL et\u00a0al (2024) Immune Checkpoint Inhibitor Myopathy: The Double-Edged Sword of Cancer Immunotherapy. Neurology 103:e210031","journal-title":"Neurology"},{"key":"1878_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/imr.13240","volume":"318","author":"J Gong","year":"2023","unstructured":"Gong\u00a0J, Neilan\u00a0TG, Zlotoff\u00a0DA (2023) Mediators and mechanisms of immune checkpoint inhibitor-associated myocarditis: Insights from mouse and human. Immunol Rev 318:70\u201380","journal-title":"Immunol Rev"},{"key":"1878_CR20","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1016\/S1470-2045(25)00651-5","volume":"27","author":"Y Kim","year":"2026","unstructured":"Kim\u00a0Y, Bates\u00a0JE, Yoon\u00a0HI et\u00a0al (2026) Cardiac radiosensitivity in the era of thoracic chemoradiotherapy and immunotherapy: a scoping review. Lancet Oncol 27:e130\u2013e140","journal-title":"Lancet Oncol"},{"key":"1878_CR21","doi-asserted-by":"crossref","unstructured":"Siddiqui BA (2023) Identifying molecular targets for rational immunosuppressive strategies in patients with immune checkpoint therapy-induced myocarditis and myositis. J\u00a0Clin Oncol\u00a041 (suppl\u00a016; abstr 2511)","DOI":"10.1200\/JCO.2023.41.16_suppl.2511"},{"key":"1878_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2025.123414","volume":"470","author":"K Sumi","year":"2025","unstructured":"Sumi\u00a0K, Masuda\u00a0T, Kondo\u00a0H et\u00a0al (2025) Cardiac involvement and anti-striational antibodies in immune-mediated necrotizing myopathy. J\u00a0Neurol Sci 470:123414","journal-title":"J Neurol Sci"},{"key":"1878_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50996-5","volume":"15","author":"SJ Sun","year":"2024","unstructured":"Sun\u00a0SJ, Jiao\u00a0XD, Chen\u00a0ZG et\u00a0al (2024) Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS-STING activation. Nat Commun 15:6640","journal-title":"Nat Commun"},{"key":"1878_CR24","doi-asserted-by":"crossref","unstructured":"Warrick KA, Johansen AKZ, Jiao M et\u00a0al. (2026) Immune checkpoint inhibitor-induced myocarditis is dependent on CD8 T\u00a0cell-derived TNF and TNFR2 signaling. J\u00a0Exp Med 223","DOI":"10.1084\/jem.20251717"},{"key":"1878_CR25","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/mus.28194","volume":"70","author":"AJ Boon","year":"2024","unstructured":"Boon\u00a0AJ, Meiling\u00a0JB, Luetmer\u00a0MT et\u00a0al (2024) Paradoxical thinning of the diaphragm on ultrasound is a\u00a0risk factor for requiring non-invasive ventilation in patients with neuromuscular diaphragmatic dysfunction. Muscle Nerve 70:352\u2013359","journal-title":"Muscle Nerve"},{"key":"1878_CR26","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1136\/thx.38.8.616","volume":"38","author":"NM Braun","year":"1983","unstructured":"Braun\u00a0NM, Arora\u00a0NS, Rochester\u00a0DF (1983) Respiratory muscle and pulmonary function in polymyositis and other proximal myopathies. Thorax 38:616\u2013623","journal-title":"Thorax"},{"key":"1878_CR27","doi-asserted-by":"publisher","first-page":"5753","DOI":"10.1093\/rheumatology\/keab249","volume":"60","author":"A Weill","year":"2021","unstructured":"Weill\u00a0A, Delyon\u00a0J, Descamps\u00a0V et\u00a0al (2021) Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a\u00a0national multicentre study. Rheumatology (Oxford) 60:5753\u20135764","journal-title":"Rheumatology (Oxford)"},{"key":"1878_CR28","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","volume":"13","author":"JE Salem","year":"2023","unstructured":"Salem\u00a0JE, Bretagne\u00a0M, Abbar\u00a0B et\u00a0al (2023) Abatacept\/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. Cancer Discov 13:1100\u20131115","journal-title":"Cancer Discov"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01878-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-026-01878-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01878-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:07:12Z","timestamp":1791400032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-026-01878-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":28,"alternative-id":["1878"],"URL":"https:\/\/doi.org\/10.1007\/s00393-026-01878-2","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.\u00a0Gente: keine Interessenskonflikte bezogen auf diese Publikation. Honoraria f\u00fcr Vortr\u00e4ge zu irAEs von AbbVie, BMS, Galapagos, Janssen, Lilly, MSD, Novartis, Regeneron, Sandoz, UCB und Viatris. K.\u00a0Kastrati berichtet \u00fcber Honorare f\u00fcr Vortr\u00e4ge und Pr\u00e4sentationen von Boehringer Ingelheim, Novartis, Eli Lilly und AbbVie sowie \u00fcber Unterst\u00fctzung f\u00fcr die Teilnahme an Tagungen und\/oder Reisekosten durch AbbVie, Johnson & Johnson und Eli Lilly. H.\u00a0Lechner-Radner: keine Interessenskonflikte bezogen auf diese Publikation. R.\u00a0Hasseli-Fr\u00e4bel: keine Interessenskonflikte bezogen auf diese Publikation.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}